Purification and Characterization of a toxic AD associated intracellularly generated amyloid beta fragment
Purification and Characterization of a toxic AD associated intracellularly generated amyloid beta fragment
批准号:
10511148
负责人:
MICHAEL R SIERKS
金额:
$43.18万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-08-01 至 2024-07-31
关键词:
3-DimensionalAgeAlzheimer&aposs DiseaseAlzheimer&aposs disease brainAmyloid beta-ProteinAmyloid beta-Protein PrecursorAntibodiesAutopsyBindingBiochemicalBrainCell Culture TechniquesCell LineCellsCharacteristicsClinical TrialsCognitiveConfusionCryoelectron MicroscopyDementiaDevelopmentDiseaseDisease ProgressionElementsFailureFoundationsFutureGenerationsGoalsHealthHeterogeneityHumanImmunoglobulin FragmentsImmunoprecipitationInflammationLinkLiteratureMammalian CellMass Spectrum AnalysisMethodsMicrotubule-Associated ProteinsModelingMolecular ConformationNerve DegenerationNeurodegenerative DisordersNeurofibrillary TanglesNeuronsPathologicPathologyPharmaceutical PreparationsPlayPost-Translational Protein ProcessingProcessProtein ConformationProteinsReproducibilityResearchRoleSamplingSenile PlaquesStructureTherapeuticToxic effectVariantabeta accumulationalpha synucleinbiophysical analysisbrain tissuecellular targetingdirect applicationeconomic costeffective therapyextracellularimprovedin vivomind controlneurotoxicnoveloAβoverexpressionprotein TDP-43protein aggregationproteostasissuccesssymptom treatmenttargeted treatmenttau Proteinstherapeutic targetthree dimensional structuretool
中文摘要
摘要
美国有500多万阿尔茨海默病(AD)病例,预计病例数量接近
在接下来的15年里翻一番,每年的总经济成本将超过225亿美元。尽管如此,还是有
仍然没有有效的治疗AD的方法。淀粉样β蛋白长期以来一直被认为与阿尔茨海默病有关,但人们对此感到困惑
淀粉样β蛋白在阿尔茨海默病中的作用仍然存在,针对淀粉样β蛋白的治疗效果有限。
淀粉样斑块是AD的标志性特征,但斑块负荷与AD进展没有很好的相关性,并且
研究表明,相关的神经毒性物质是低聚淀粉样β蛋白,而不是纤维样蛋白。
在公元后。在体内,淀粉样β蛋白是一种非常不同的蛋白质,并且有许多截然不同的单体和聚集态
人类阿尔茨海默病的大脑中存在变异体。由于蛋白质构象与功能直接相关,因此确定
关键的Aβ变异体的构象对于理解它们在AD中的机制作用至关重要。然而,3-
与阿尔茨海默病神经变性有关的相关寡聚体淀粉样β变异体的D结构仍然难以捉摸。这
可能是由于不同的寡聚体淀粉样β变异体只在很低的水平上存在于
人类AD样本使结构分析变得困难。拟议的研究直接集中在这一点上
问题:在这里,我们将产生并表征在人类阿尔茨海默病中发现的关键的低聚淀粉样β聚集体
使用我们实验室开发的抗体衍生工具(Fabs),大脑但不是认知正常的脑组织。C6T
FAB选择性地识别存在的关键的细胞内产生的淀粉样β蛋白的寡聚聚体
在AD脑组织中,而不是来自认知正常的年龄匹配的对照脑组织的组织中。C6T Fab将
作为拟议研究的基础,该研究旨在使完整的结构和生化
阿尔茨海默病脑组织中发现的有毒低聚体淀粉样β蛋白的特征。将使用C6T FAB
通过免疫沉淀分离有毒的细胞内产生的淀粉样β变异体。质谱学将
然后用来确定产生的聚集体的蛋白质组成。由于生成的聚合
由于广泛的翻译后修饰,来自人脑组织的可能是相当不同的
人类大脑中的淀粉样β蛋白,我们也将类似地分离和鉴定有毒细胞产生的淀粉样β蛋白
在哺乳动物细胞系7PA2中产生的聚集体。这些研究将提供框架,以便进一步
这一关键的淀粉样β变异体的三维特性研究。我们已经组建了一支具有独特能力的团队
在FAB的开发中,3D结构确定和蛋白质建模来执行这些研究。结构性
不同的寡聚体淀粉样β蛋白物种的信息对于我们理解
它们与不同的细胞靶点相互作用,并帮助设计适当的治疗策略。这些方法
可以很容易地应用于其他与神经退行性疾病有关的关键蛋白质变体,包括tau,
α-突触核蛋白和TDP-43。
英文摘要
ABSTRACT
There are over 5 million cases of Alzheimer’s disease (AD) in the US, the number of cases is expected to nearly
double over the next 15 years, and the total annual economic costs are over $225 billion. Despite this, there is
still no effective treatment for AD. The protein amyloid-beta has long been linked to AD, but much confusion over
the role of amyloid-beta in AD still exists and therapeutics targeting amyloid-beta have had limited success.
Amyloid plaques are hallmark features of AD, but plaque loads do not correlate well with AD progression, and
studies suggest that oligomeric amyloid-beta forms rather than fibrillar forms are the relevant neurotoxic species
in AD. In vivo, amyloid-beta is a very heterogeneous protein, and many distinct monomeric and aggregated
variants are present in human AD brain. Since protein conformation is directly related to function, determining
the conformations of key Aβ variants is crucial to understanding their mechanistic roles in AD. However, the 3-
D structures of relevant oligomeric amyloid-beta variants involved in AD neurodegeneration remain elusive. This
is likely due to the fact that the different oligomeric amyloid-beta variants are present at only very low levels in
human AD samples making structural analysis difficult. The proposed research is focused directly on this
problem: here we will generate and characterize a key oligomeric amyloid-beta aggregates found in human AD
brain but not cognitively normal brain tissue using antibody derived tools (Fabs) generated in our lab. The C6T
Fab selectively recognizes a key intracellularly generated oligomeric aggregates of amyloid-beta that is present
in AD brain tissue but not tissue from cognitively normal age-matched control brain tissue. The C6T Fab will
serve as the foundation of the proposed research, which seeks to enable the complete structural and biochemical
characterization of the toxic oligomeric forms of amyloid-beta found in AD brain tissue. The C6T Fab will be used
to isolate the toxic intracellularly generated amyloid-beta variant via immunoprecipitation. Mass spectrometry will
then be used to determine the protein composition of the generated aggregates. Since the aggregates generated
from human brain tissue may be quite heterogeneous due to the extensive post-translational modifications of
amyloid-beta in human brain, we will also similarly isolate and characterize the toxic cell generated amyloid-beta
aggregate as generated in the mammalian cell line, 7PA2. These studies will provide the framework for further
3-D characterization studies of this key amyloid-beta variant. We have assembled a team with unique capabilities
in Fab development, 3-D structure determination and protein modeling to perform these studies. Structural
information of the different oligomeric amyloid-beta species will be vitally important to our understanding of how
they interact with different cellular targets and to help devise appropriate therapeutic strategies. These methods
could be easily applied to other key protein variants implicated in neurodegenerative diseases including tau,
alpha-synuclein and TDP-43.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Protein variants as blood based biomarkers for diagnosing and staging AD
-
批准号:9977069
-
项目类别:
-
资助金额:$34.96万
-
财政年份:2016
-
负责人:MICHAEL R SIERKS
-
依托单位:
Protein variants as blood based biomarkers for diagnosing and staging AD
-
批准号:9334047
-
项目类别:
-
资助金额:$34.96万
-
财政年份:2016
-
负责人:MICHAEL R SIERKS
-
依托单位:
Nanobodies selective for oligomeric Tau species isolated from AD brain
-
批准号:8633097
-
项目类别:
-
资助金额:$23.83万
-
财政年份:2013
-
负责人:MICHAEL R SIERKS
-
依托单位:
Nanobodies selective for oligomeric Tau species isolated from AD brain
-
批准号:8741902
-
项目类别:
-
资助金额:$19.31万
-
财政年份:2013
-
负责人:MICHAEL R SIERKS
-
依托单位:
Developing Diagnostic Nanobodies Against Aggregated TDP-43 Species
-
批准号:8386058
-
项目类别:
-
资助金额:$24.55万
-
财政年份:2012
-
负责人:MICHAEL R SIERKS
-
依托单位:
Developing Diagnostic Nanobodies Against Aggregated TDP-43 Species
-
批准号:8517544
-
项目类别:
-
资助金额:$18.27万
-
财政年份:2012
-
负责人:MICHAEL R SIERKS
-
依托单位:
Intracellular tools to study specific misfolded protein variants in human disease
-
批准号:8307797
-
项目类别:
-
资助金额:$15.34万
-
财政年份:2011
-
负责人:MICHAEL R SIERKS
-
依托单位:
Intracellular tools to study specific misfolded protein variants in human disease
-
批准号:8191309
-
项目类别:
-
资助金额:$18.19万
-
财政年份:2011
-
负责人:MICHAEL R SIERKS
-
依托单位:
INHIBITING AGGREGATION WITH PHAGE DISPLAY ANTIBODIES
-
批准号:6092779
-
项目类别:
-
资助金额:$17.87万
-
财政年份:2000
-
负责人:MICHAEL R SIERKS
-
依托单位:
INHIBITING AGGREGATION WITH PHAGE DISPLAY ANTIBODIES
-
批准号:6372479
-
项目类别:
-
资助金额:$18.75万
-
财政年份:2000
-
负责人:MICHAEL R SIERKS
-
依托单位:
INHIBITING AGGREGATION WITH PHAGE DISPLAY ANTIBODIES
-
批准号:6631468
-
项目类别:
-
资助金额:$25.6万
-
财政年份:2000
-
负责人:MICHAEL R SIERKS
-
依托单位:
INHIBITING AGGREGATION WITH PHAGE DISPLAY ANTIBODIES
-
批准号:6509737
-
项目类别:
-
资助金额:$18.75万
-
财政年份:2000
-
负责人:MICHAEL R SIERKS
-
依托单位:
INHIBITING AGGREGATION WITH PHAGE DISPLAY ANTIBODIES
-
批准号:6685537
-
项目类别:
-
资助金额:$4.39万
-
财政年份:2000
-
负责人:MICHAEL R SIERKS
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: